Avutometinib Potassium 0.8 mg, 200 mg Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 0.8 mg, 200 mg
Reference Brands: Avmapki (USA), Fakzynja (USA)
Category: Oncology Cancer Care
Avutometinib Potassium is a Oncology Cancer Care product available as Capsules in strengths 0.8 mg, 200 mg. It corresponds to the reference brands Avmapki (USA), Fakzynja (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.
Manufacture or export Avutometinib Potassium? List it or send an offer →
Product Description:
Avutometinib potassium (CH5126766) is a small-molecule kinase inhibitor designed to block the RAF/MEK signaling pathway in cancer cells. It functions as a RAF/MEK clamp, potently inhibiting RAF and MEK kinase activity while inducing dominant-negative RAF-MEK complexes that prevent MEK phosphorylation by ARAF, BRAF, and CRAF. This mechanism effectively suppresses tumor cell proliferation, particularly in cell lines harboring KRAS mutations, including pancreatic ductal adenocarcinoma (PDAC) models. Preclinical studies demonstrate that Avutometinib potassium inhibits tumor growth and improves survival in KRAS/p53 pancreatic cancer mouse models. The compound shows promise for targeted therapy research in low-grade serous ovarian carcinoma (LGSOC), ovarian cancer, and pancreatic cancers, offering a precision oncology approach to treatment. Administered orally in capsule form, Avutometinib potassium is being investigated both as a single agent and in combination therapies to enhance anti-cancer efficacy. Its ability to disrupt critical cancer cell signaling pathways highlights its potential as a valuable therapeutic option in the development of next-generation treatments for KRAS-driven malignancies.
How Avutometinib Potassium is supplied today, and licensing ahead of patent expiry
Where avutometinib with defactinib is approved
Checked 3 Oct 2026| Market | Status | Brand · regulator · date |
|---|---|---|
| United States | Approved | Avmapki Fakzynja Co-Pack · FDA · May 2025 (accelerated) |
| Generic / biosimilar | None | None approved as of the check date |
Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →
Frequently Asked Questions
It is used, as part of combination therapy with defactinib, to treat KRAS-mutated recurrent low-grade serous ovarian cancer in adults after prior systemic therapy.
Avutometinib potassium is a kinase inhibitor, a potassium salt of a small molecule designed to inhibit RAF and MEK kinases, with the molecular formula C₂₁H₁₇FKN₅O₅S.
Avmapki Fakzynja Co‑Pack (co-packaged with defactinib).
Manufactured by Verastem Oncology under regulated pharmaceutical standards.
Avutometinib potassium
Avmapki Fakzynja Co‑Pack
Manufactured under regulated standards by Verastem Oncology and supply partners in the United States.
Avmapki Fakzynja Co-Pack (Avutometinib + Defactinib) is developed and sold by Verastem Oncology. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.
Related Products
Gemcitabine Hydrochloride
Strength:
200 mg, 1 g, 2 g
Form: Injection
Reference Brands: Gemzar (USA), Infugem (USA), Avgemsi (USA)
View Details
Pemetrexed Dipotassium
Strength:
100 mg, 500 mg
Form: Injection
Reference Brands: Alimta (USA), Pemfexy (USA)
View Details
Levoleucovorin
Strength:
5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 175 mg, 250 mg
Form: Tablet / Injection
Reference Brands: Fusilev (USA), Khapzory (USA)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit
